Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Proposes Rule On Gluten-Free Labeling

This article was originally published in The Tan Sheet

Executive Summary

Food products with "gluten-free" claims will be misbranded if they do not meet the conditions of a proposed rule FDA published in the Jan. 23 Federal Register

You may also be interested in...



Compliance For ‘Gluten Free’ Claims For Fermented, Hydrolyzed Supplements Relies On Recordkeeping

Final rule amends FDA regulation on gluten-free labeling to provide alternative means for the agency to verify compliance. It will determine whether a firm is compliant from records it must maintain, and make available for inspection and copying, of the fermented or hydrolyzed supplements and food products bearing the claim.

Gluten-Drug Rule Petitioner Claims Time Has Expired For FDA Decision

A lawsuit seeks to declare FDA’s failure to act on a 2008 citizen petition requesting a ban of wheat gluten in OTCs and Rx drugs in violation of the Administrative Procedure Act. The complaint alleges the agency’s delay is unreasonable and asks the court to order FDA to make a decision within 30 days.

Gluten-Drug Rule Petitioner Claims Time Has Expired For FDA Decision

A lawsuit seeks to declare FDA’s failure to act on a 2008 citizen petition requesting a ban of wheat gluten in OTCs and Rx drugs in violation of the Administrative Procedure Act. The complaint alleges the agency’s delay is unreasonable and asks the court to order FDA to make a decision within 30 days.

Related Content

Topics

UsernamePublicRestriction

Register

PS100160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel